Cynapsus Therapeutics' APL 130277 for Parkinson's Chosen As

Cynapsus Therapeutics' APL 130277 for Parkinson's Chosen As One Of
The Top Ten Neurology Projects To Watch For 2012 
-Independent Committee Selects Cynapsus' Novel Sublingual formulation
of Apomorphine, as One of the Most Promising CNS Candidates- 
TORONTO, ONTARIO -- (Marketwire) -- 10/29/12 -- Cynapsus Therapeutics
Inc. (TSX VENTURE:CTH) today announced that its APL-130277 for
Parkinson's was recognized as one of the Top Ten Neurology Projects
to Watch in 2012 by a joint selection committee including Dr. Harry
Tracy, a noted authority on pharmacological interventions for
diseases of the brain and editor of the highly respected
biotechnology publication NeuroPerspective, as well as with Elsevier
Business Intelligence, the publishers of In Vivo, Startup and The
Pink Sheet. Cynapsus has been invited to present the APL-130277
Project at Elsevier's Therapeutic Area Partnerships Meeting taking
place on November 28-30, 2012 at the Westin Copley in Boston.  
Criteria for selection of the Top 10 Neurology Projects to Watch in
2012 were: 


 
--  Large market, large unmet need, with increasing opportunity 
--  History of the molecule and drug 
--  Strong science 
--  Strong company 
--  Diversity of indications 
--  Potential for new opportunities beyond the initial indications 
--  Multi-level partnering opportunities, i.e., biotech to biotech as well
    as pharma to biotech 

 
APL-130277 is a unique and innovative, sublingual thin film strip
formulation of apomorphine. Apomorphine is an approved drug
prescribed in the US, Europe and several other countries. It is
administered as a subcutaneous injection or infusion to Parkinson's
patients experiencing daily "OFF" or motor fluctuation episodes.
APL-130277 would provide patients with a convenient and more
tolerable alternative to multiple daily injections. As a new means of
delivering an approved drug, this clinical stage project is expected
to follow a bioequivalence regulatory and clinical path which would
culminate in a New Drug Approval application in 2015. 
"We are humbled to be recognized from among several hundred worthy
neuroscience projects, worldwide. This is a significant honor and
further independent validation of the potential of APL-130277. This
comes only a few months after receiving a significant grant from The
Michael J. Fox Foundation for Parkinson's Research (MJFF) to help
support our next clinical study (CTH103). The MJFF Clinical
Intervention Award was provided through the Edmond J. Safra Core
Programs for Parkinson's Research," said Mr. Anthony Giovinazzo,
President and Chief Executive Officer of Cynapsus. "Since we started
this project, we determined that there are a large number of
Parkinson's patients who would benefit from needle-free delivery of
the drug. This includes patients who want a convenient alternative to
a very painful injection regimen, patients who have resisted
initiating therapy because of the needle issues, and the increase in
PD population as a result of the growing aging baby boomer
generation. These factors combined indicate that the number of
Parkinson's patients worldwide could potentially increase 2-to-3 fold
over the next 8 to 10 years. This significant potential unmet medical
need coupled with a short and lower risk clinical pathway would be of
interest to many in global and specialty pharma, especially given
that our pending patent estate, when approved and granted, would
provide protection to 2031 at a minimum." 
About Parkinson's Disease  
Parkinson's disease is a chronic, degenerative neurological disorder
that results from the loss of dopamine-producing nerve cells in the
brain. Current treatments for Parkinson's disease are able to reduce
the symptoms of the disease but are not able to treat the underlying
neurodegenerative processes that lead to a decline in physical and
cognitive functions that affects some patients with Parkinson's
disease. It is estimated that over one million people in the United
States and 5 million people globally are living with Parkinson's
disease. According to the National Institute of Neurodegenerative
Disease and Stroke, the average age of onset is 60, although some
people are diagnosed at age 40 or younger. 
About Cynapsus Therapeutics  
Cynapsus is a specialty pharmaceutical company developing the only
orally administered convenient (sublingual) delivery of the only
approved drug (apomorphine) to treat the motor symptoms of
Parkinson's disease. Over one million people in the United States and
an estimated 5 million people globally suffer from Parkinson's
disease. Parkinson's disease is a chronic and progressive
neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. Based on
the IMPACT Registry Study and the results of Cynapsus' Global 500
Neurologists Survey, is estimated that between 25 percent and 50
percent of patients experience "OFF episodes" in which they have
impaired movement or speaking capabilities. Current medications only
control the disease's symptoms, and most drugs become less effective
over time as the disease progresses.  
Cynapsus' lead drug candidate, APL-130277, is an easy-to-administer,
fast-acting reformulation of an approved drug, apomorphine, used to
rescue patients from OFF episodes. Cynapsus is focused on rapidly
maximizing the value of APL-130277 by completing pivotal studies in
advance of a New Drug Application expected to be submitted in 2015.
Cynapsus anticipates out-licensing to an appropriate pharmaceutical
partner before such an application is submitted.  
More information about Cynapsus (TSX VENTURE:CTH) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis
and Retrieval (SEDAR) at www.sedar.com.  
About TA Partnerships  
Elsevier's 7th Annual Therapeutic Area Partnerships is the industry's
most targeted and efficient partnering meeting for life science
companies seeking partnerships in the top therapeutic areas:
Oncology, Cardiovascular/Metabolic, Neuroscience, Infectious,
Inflammatory Diseases and other hot therapeutic areas.
Decision-makers focusing on these therapeutic categories can meet to
develop strategic alliances in a personal and interactive setting
that combines company presentations, 1:1 meetings and networking
functions. More information is available at
http://www.tapartnerships.com/content/Main.aspx  
About Elsevier Business Intelligence 
Elsevier Business Intelligence, a global leader in the field of
healthcare industry information, provides business intelligence on
regulatory, business and reimbursement issues that are vital to the
healthcare industry. Through a range of products including
publications, conferences, e-learning, databases and reports,
Elsevier Business Intelligence places biopharma and medical device
professionals, and those who focus on these industries, at the
forefront of knowledge, by providing the perfect combination of news
and information together with penetrating insight and analysis. Our
leading publications include PharmAsia News, IN VIVO and "The Pink
Sheet." For more information, visit: http://www.ElsevierBi.com  
Forward Looking Statements 
This announcement contains "forward-looking statements" within the
meaning of applicable Canadian securities legislation. Generally,
these forward-looking statements can be identified by the use of
forward-looking terminology such as "plans", "expects" or "does not
expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or
"believes" or variations of such words and phrases or state that
certain actions, events or results "may", "could", "would", "might"
or "will be taken", "occur" or "be achieved". Forward-looking
statements are subject to known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity,
performance or achievements of Cynapsus to be materially different
from those expressed or implied by such forward-looking statements,
including but not limited to those risks and uncertainties relating
to Cynapsus' business disclosed under the heading "Risk and
Uncertainties" in "Management's Discussion and Analysis of Operating
Results and Financial Condition" for the year ended December 31,
2011, and its other filings with the various Canadian securities
regulators which are available online at www.sedar.com. Although
Cynapsus has attempted to identify important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can be
no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements. Cynapsus does not
undertake to update any forward-looking statements, except in
accordance with applicable securities laws.
Contacts:
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg@cynapsus.ca 
Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams@cynapsus.ca